A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Inclusion criteria:

• Japanese males, 20-64 years of age, inclusive
• Body weight >50Kg
• Body Mass Index (BMI): 18-28
• Subjects must have lived outside of Japan no more than 10 years
• Non-smoker or smokes fewer than 10 cigarettes/day

Exclusion criteria:

• History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses
• History of sensitivity to heparin or heparin-induced thrombocytopenia
• History of alcohol/drug abuse or dependence within 12 months of the study
• Positive syphilis, HIV antibody, Hepatitis B, Hepatitis C
• History of cholecystectomy or biliary tract disease or history of liver disease
• Participation in a clinical study within 30 days prior to first dose
• Subject has been exposed to more than 4 chemical entities within 12 months
• Positive urine drug and alcohol at screening
• Subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons.